News Bulletin 26th February 2024

The latest from National Health Executive

What is National Health Executive News?

Daily News from National Health Executive

And here’s today’s news from National Health Executive on Monday the 26th of February 2024
NICE has made a new recommendation for a drug to treat severe alopecia, which is expected to benefit up to 14,000 people. The treatment, which is manufactured by Pfizer, was rejected by NICE last September but has now been approved following an additional discount.
Clinical trial data showed Pfizer’s drug was more effective than a placebo at improving hair regrowth, with response rates sustaining for up to two years.
Early trials of a drug derived from olive oil has shown promise as a treatment for brain cancer. A trial at the Royal Marsden NHS Foundation Trust found that 24% of glioblastoma patients responded positively to the treatment.
The NHS is now launching a phase 3 trial to further test the drug, which will recruit over 200 newly diagnosed patients.
A £1.5m clinical trial is set to examine the effectiveness of proton beam therapy compared to standard radiotherapy. It is hoped that proton beam therapy can lead to fewer long-term side effects and improve cancer care for future patients.
The trial will be led by the University of Leeds and tested on brain cancer patients. The study is being funded through the Efficacy Mechanism Evaluation programme, which is a partnership between the Medical Research Council and the NIHR.
And that’s the latest – Don’t forget to like and subscribe to make sure you receive every new bulletin & check out our website National Health Executive .com